LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibb’s OPDIVO®

LabCorp Performed Testing for Studies Supporting Approval of Two New Complementary Diagnostic Indications in Connection with the Treatment of Bladder Cancer and Cancer of the Head and Neck BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 15, 2017-- LabCorp (NYSE: LH) a leading global life sciences company,

LabCorp Receives 2017 Partnership Award from Be The Match®

Award Recognizes 25 Years of Innovation and Support to Help Cure Blood Cancers BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 13, 2017-- LabCorp, (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, proudly announces that it received the 2017 Partnership

LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 16th Annual Scorecard on LGBTQ Workplace Equality

Receives Designation as a Best Place to Work for LGBTQ Equality BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 13, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, announced that it received a perfect score of 100 percent on the 2018 Corporate Equality Index (CEI), a national

LabCorp is Scheduled to Present at the 26th Annual Credit Suisse Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 1, 2017-- LabCorp ® (NYSE: LH) today announced it will participate at the 26th Annual Credit Suisse Healthcare Conference . LabCorp’s presentation is planned for Tuesday, November 7, 2017 at 10:55 am (MT) . A live audio webcast will be available via the

LabCorp and Capital Health Enter Comprehensive Laboratory Partnership

Collaboration Will Enhance and Streamline Laboratory Services for Patients and Physicians in Central New Jersey and Lower Bucks County, Pennsylvania BURLINGTON, N.C. & TRENTON, N.J. --(BUSINESS WIRE)--Nov. 1, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, and Capital Health ,

LabCorp Announces Record Third Quarter Results and Increases 2017 Guidance

Q3 Net revenue of $2.6 billion , up 10% over last year Q3 Diluted EPS of $1.74 , up 2% from last year; Q3 Adjusted EPS of $2.46 , up 9% over last year 2017 Adjusted EPS guidance increased to $9.40 to $9.60 , up 6% to 9% over 2016 2017 Free Cash Flow guidance increased to $970 million to $1,010

Covance Recognized with Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 16, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development business (Covance) has been awarded the 2017 Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award.

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 2, 2017-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject

LabCorp Objects to Proposed PAMA 2018 Medicare Payment Rates for Clinical Laboratory Tests; Calls for Delay in Implementation to Avoid Significant Harm to Medicare Beneficiaries

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 25, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, today issued the following response to the Sept. 22 publication by the Centers for Medicare and Medicaid Services (CMS) of proposed 2018 Medicare reimbursement rates for clinical

LabCorp Presents Nine Studies, Including Novel Research on Improving Genetic Counseling Quality, at the National Society of Genetic Counselors Annual Conference

LabCorp’s Integrated Genetics Specialty Laboratory Leverages Decades of Experience in Genetics Research and Practice to Improve Health and Improve Lives BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 14, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, announced today that Integrated